nach oben

Erschienen in:

01.01.2010 | Original Paper

Race, healthcare access and physician trust among prostate cancer patients

verfasst von: Young Kyung Do, William R. Carpenter, Pamela Spain, Jack A. Clark, Robert J. Hamilton, Joseph A. Galanko, Anne Jackman, James A. Talcott, Paul A. Godley

Erschienen in: Cancer Causes & Control | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective

To study the effect of healthcare access and other characteristics on physician trust among black and white prostate cancer patients.

Methods

A three-timepoint follow-up telephone survey after cancer diagnosis was conducted. This study analyzed data on 474 patients and their 1,320 interviews over three time periods.

Results

Among other subpopulations, black patients who delayed seeking care had physician trust levels that were far lower than that of both Caucasians as well as that of the black patients overall. Black patients had greater variability in their levels of physician trust compared to their white counterparts.

Conclusions

Both race and access are important in explaining overall lower levels and greater variability in physician trust among black prostate cancer patients. Access barriers among black patients may spill over to the clinical encounter in the form of less physician trust, potentially contributing to racial disparities in treatment received and subsequent outcomes. Policy efforts to address the racial disparities in prostate cancer should prioritize improving healthcare access among minority groups.

American Cancer Society (2007) Cancer facts & figures 2007. American Cancer Society, Atlanta, GA

Gilligan T (2005) Social disparities and prostate cancer: mapping the gaps in our knowledge. Cancer Causes Control 16:45–53CrossRefPubMed

Gilligan T, Wang PS, Levin R, Kantoff PW, Avorn J (2004) Racial differences in screening for prostate cancer in the elderly. Arch Intern Med 164:1858–1864CrossRefPubMed

Etzioni R, Berry KM, Legler JM, Shaw P (2002) Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 1991–1998. Urology 59:251–255CrossRefPubMed

Hoffman RM, Gilliland FD, Eley JW et al (2001) Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93:388–395CrossRefPubMed

Polednak AP, Flannery JT (1992) Black versus white racial differences in clinical stage at diagnosis and treatment of prostatic cancer in Connecticut. Cancer 70:2152–2158CrossRefPubMed

Roetzheim RG, Pal N, Tennant C et al (1999) Effects of health insurance and race on early detection of cancer. J Natl Cancer Inst 91:1409–1415CrossRefPubMed

Merrill RM, Lyon JL (2000) Explaining the difference in prostate cancer mortality rates between white and black men in the United States. Urology 55:730–735CrossRefPubMed

Vijayakumar S, Weichselbaum R, Vaida F, Dale W, Hellman S (1996) Prostate-specific antigen levels in African-Americans correlate with insurance status as an indicator of socioeconomic status. Cancer J Sci Am 2:225–233PubMed

10.

Moul JW, Sesterhenn IA, Connelly RR et al (1995) Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 274:1277–1281CrossRefPubMed

11.

Polednak AP (2002) Black-white differences in tumor grade (aggressiveness) at diagnosis of prostate cancer, 1992–1998. Ethn Dis 12:536–540PubMed

12.

Fowler JE Jr, Bigler SA, Bowman G, Kilambi NK (2000) Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment. J Urol 163:137–142CrossRefPubMed

13.

Rose AJ, Backus BM, Gershman ST, Santos P, Ash AS, Battaglia TA (2007) Predictors of aggressive therapy for nonmetastatic prostate carcinoma in Massachusetts from 1998 to 2002. Med Care 45:440–447CrossRefPubMed

14.

Zeliadt SB, Potosky AL, Etzioni R, Ramsey SD, Penson DF (2004) Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology 64:1171–1176CrossRefPubMed

15.

Shavers VL, Brown ML, Potosky AL et al (2004) Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med 19:146–155CrossRefPubMed

16.

Harlan LC, Potosky A, Gilliland FD et al (2001) Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 93:1864–1871CrossRefPubMed

17.

Klabunde CN, Potosky AL, Harlan LC, Davis WW, Potosky AL (1998) Trends and black/white differences in treatment for nonmetastatic prostate cancer. Med Care 36:1337–1348CrossRefPubMed

18.

Schapira MM, McAuliffe TL, Nattinger AB (1995) Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease. Med Care 33:1079–1088CrossRefPubMed

19.

Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD (2003) Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer 98:496–503CrossRefPubMed

20.

Shavers VL, Brown M, Klabunde CN et al (2004) Race/ethnicity and the intensity of medical monitoring under ‘watchful waiting’ for prostate cancer. Med Care 42:239–250CrossRefPubMed

21.

Cohen JH, Schoenbach VJ, Kaufman JS et al (2006) Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States). Cancer Causes Control 17:803–811CrossRefPubMed

22.

Godley PA, Schenck AP, Amamoo MA et al (2003) Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 95:1702–1710PubMed

23.

Allen JD, Kennedy M, Wilson-Glover A, Gilligan TD (2007) African-American men’s perceptions about prostate cancer: implications for designing educational interventions. Soc Sci Med 64:2189–2200CrossRefPubMed

24.

Myers RE, Daskalakis C, Cocroft J et al (2005) Preparing African-American men in community primary care practices to decide whether or not to have prostate cancer screening. J Natl Med Assoc 97:1143–1154PubMed

25.

Institute of Medicine (IOM) (2003) Unequal treatment: confronting racial and ethnic disparities in healthcare. The National Academies Press, Washington, DC

26.

Steele CB, Miller DS, Maylahn C, Uhler RJ, Baker CT (2000) Knowledge, attitudes, and screening practices among older men regarding prostate cancer. Am J Public Health 90:1595–1600CrossRefPubMed

27.

Demark-Wahnefried W, Strigo T, Catoe K et al (1995) Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. Urology 46:346–351CrossRefPubMed

28.

Talcott JA, Spain P, Clark JA et al (2007) Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer 109:1599–1606CrossRefPubMed

29.

Beskow LM, Millikan RC, Sandler RS, Godley PA, Weiner BJ, Weinberger M (2006) The effect of physician permission versus notification on research recruitment through cancer registries. Cancer Causes Control 17:315–323CrossRefPubMed

30.

Safran DG, Kosinski M, Tarlov AR et al (1998) The Primary Care Assessment Survey: tests of data quality and measurement performance. Med Care 36:728–739CrossRefPubMed

31.

Kilbourne AM, Switzer G, Hyman K, Crowley-Matoka M, Fine MJ (2006) Advancing health disparities research within the health care system: a conceptual framework. Am J Public Health 96:2113–2121CrossRefPubMed

32.

LaVeist TA (1994) Beyond dummy variables and sample selection: what health services researchers ought to know about race as a variable. Health Serv Res 29:1–16PubMed

33.

Kennedy P (2003) A guide to econometrics. The MIT Press, Cambridge, MA

34.

Taira DA, Safran DG, Seto TB et al (2001) Do patient assessments of primary care differ by patient ethnicity? Health Serv Res 36:1059–1071PubMed

35.

Safran DG (2003) Measuring the quality of the primary care relationship. In: Dube L, Ferland G, Moskowitz, DS (eds) Emotional and interpersonal dimensions of health services, Chap 2. McGill-Queens University Press, New York, pp 12–44

36.

AHRQ (2006) Access to care. National Healthcare Disparities Report, Chap 3. Rockville, MD, U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality; December 2006. AHRQ Pub. No. 07-0012

37.

Andersen RM, Davidson PL (2007) Improving access to care in America. In: Andersen RM, Rice TH, Kominski GF (eds) Changing the U.S. health care system, Chap 1. Jossey-Bass, San Francisco, pp 3–31

38.

Karpati A, Galea S, Awerbuch T, Levins R (2002) Variability and vulnerability at the ecological level: implications for understanding the social determinants of health. Am J Public Health 92:1768–1772CrossRefPubMed

39.

Levins R, Lopez C (1999) Toward an ecosocial view of health. Int J Health Serv 29:261–293CrossRefPubMed

40.

Eden J, Simone JV (2005) Assessing the quality of cancer care: an approach to measurement in Georgia. The National Academies Press, Washington, DC

41.

Schulman KA, Seils DM (2003) Outcomes research in oncology: improving patients’ experiences with cancer treatment. Clin Ther 25:665–670CrossRefPubMed

42.

Ganz PA (2002) What outcomes matter to patients: a physician-researcher point of view. Med Care 40:III11–III19CrossRefPubMed

43.

Cleary PD, Edgman-Levitan S (1997) Health care quality. Incorporating consumer perspectives. JAMA 278:1608–1612CrossRefPubMed

44.

Stewart AL, Napoles-Springer AM, Gregorich SE et al (2007) Interpersonal processes of care survey: patient-reported measures for diverse groups. Health Serv Res 42:1235–1256CrossRefPubMed

45.

Jayadevappa R, Chhatre S, Whittington R, Bloom BS, Wein AJ, Malkowicz SB (2006) Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy. BJU Int 97:955–962CrossRefPubMed

46.

Talcott JA, Manola J, Clark JA et al (2003) Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol 21:3979–3986CrossRefPubMed

47.

Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL (2003) Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer 97:1653–1662CrossRefPubMed

48.

Clark JA, Inui TS, Silliman RA et al (2003) Patients’ perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 21:3777–3784CrossRefPubMed

49.

Potosky AL, Reeve BB, Clegg LX et al (2002) Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 94:430–437PubMed

50.

Eton DT, Lepore SJ, Helgeson VS (2001) Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors. Cancer 92:1451–1459CrossRefPubMed

51.

Stanford JL, Feng Z, Hamilton AS et al (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 283:354–360CrossRefPubMed

52.

Clark JA, Wray N, Brody B, Ashton C, Giesler B, Watkins H (1997) Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Soc Sci Med 45:1299–1309CrossRefPubMed

Titel: Race, healthcare access and physician trust among prostate cancer patients
verfasst von: Young Kyung Do
William R. Carpenter
Pamela Spain
Jack A. Clark
Robert J. Hamilton
Joseph A. Galanko
Anne Jackman
James A. Talcott
Paul A. Godley
Publikationsdatum: 01.01.2010
Verlag: Springer Netherlands
Erschienen in: Cancer Causes & Control / Ausgabe 1/2010
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9431-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Race, healthcare access and physician trust among prostate cancer patients

Abstract

Objective

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Breastfeeding and risk of epithelial ovarian cancer

Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort

Reproductive factors, exogenous female hormone use and breast cancer risk in Japanese: the Miyagi Cohort Study

Beliefs about the causes of breast and colorectal cancer among women in the general population

Plasma enterolactone and risk of colon and rectal cancer in a case–cohort study of Danish men and women

Leukocyte telomere length in a population-based case–control study of ovarian cancer: a pilot study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie